TSHA · Taysha Gene Therapies, Inc.

The thesis

Taysha Gene Therapies' Rett syndrome gene therapy, TSHA-102, still turns on pivotal interim data and FDA feedback guided to the first half of 2027, and the shares have partly recovered from their October low without any new clinical news. The close was $4.23 on 28 October 2026, against $3.73 on 15 October 2026, and the Q3 report, expected around 10 November 2026, is the next dated test of the manufacturing and pivotal timing guidance.

The shares remain 39.4% below the $6.98 52-week high and down 27.8% over three months (adjusted daily closes). The $4.00 daily-close level published on 3 October 2026 was breached on 15 October 2026 and has been regained. The Relative Strength Index (RSI, a 0-to-100 gauge of recent buying and selling pressure) over 14 days was 45.7 on 28 October 2026, up from 28.8 on 15 October 2026 and no longer in oversold territory.

The narrative is maturing: the 22 June 2026 Part A results are well known, Taysha's 1 October 2026 release on Child Neurology Society encore presentations carried no new numerical data, and the shares have traded below the $6.00 June offering price since the 24 June 2026 pricing. Company news and SEC filings show no new clinical release or financing since 16 October 2026.

Bullish and bearish views on Taysha Gene Therapies, Inc.

The bull case on Taysha Gene Therapies, Inc. (TSHA), in brief: Funding runs past the readout. The bear case: The price remains well under the offering.

Bull case

• Funding runs past the readout. Taysha reported $455.4 million in cash and cash equivalents at 30 June 2026 and guided runway into the second half of 2028 (Q2 2026 results, 11 August 2026). Both guided clinical events fall inside that period.
• Pivotal data are guided close. Topline six-month interim data from the 17-patient REVEAL pivotal trial and FDA feedback on the filing route are both guided to the first half of 2027 (Q2 2026 results, 11 August 2026). Dosing is complete in REVEAL and in the four-patient ASPIRE trial.
• Early efficacy cleared the agreed bar. REVEAL Part A showed a 100% milestone response at 12 months in 12 patients against an FDA-aligned 33% threshold (company release, 22 June 2026). The company reported no severe treatment-related serious adverse events or dose-limiting toxicities across 33 treated patients as of the August 2026 cutoff.
• Analyst targets sit far above the price. MarketBeat reported on 10 July 2026 an average analyst target of $12.62 with a consensus Buy rating, and Needham reiterated a $12.00 target on 30 June 2026. These targets predate the decline and show where coverage stood in July.

Bear case

• The price remains well under the offering. The close of $4.23 on 28 October 2026 is below the $6.00 June offering price and 39.4% below the 52-week high. The recovery from $3.73 came with no new clinical release, so it does not yet show a change in demand.
• Regulatory route is unresolved. The pivotal trial is open-label and single-arm, and its primary endpoint is a novel scale, the Rett Syndrome Developmental Milestone Assessment. FDA feedback is not due until the first half of 2027, and the agency could still ask for controlled data.
• New supply followed the data. Taysha priced a $200 million offering at $6.00 on 24 June 2026, and the underwriters later took the full option for $230 million gross. Shares outstanding were 325.3 million afterward. The six-month net loss was $89.0 million against $48.4 million a year earlier (Q2 2026 Form 10-Q).
• Manufacturing sits at one site. Commercial manufacturing has depended on a single Catalent facility in Harmans, Maryland since 3 August 2026. Process performance qualification (PPQ), the validation run that supports a filing, is guided to finish in Q4 2026 (Q2 2026 results, 11 August 2026).
• A competitor is dosed and reading out later. Neurogene's 25-patient Embolden registrational Rett trial completed dosing, with topline guided to the second half of 2027 (Neurogene Q2 2026 update, 10 August 2026).

Price setup

The adjusted daily close was $4.23 on 28 October 2026. Closes in October ran from $4.63 on 2 October 2026 to $3.73 on 15 October 2026. The 52-week high is $6.98. The $6.00 June offering price is the nearest widely known reference above the shares, and the round-number $4.00 level is now below the price.

The shares sit well below the highs, not above a rising moving average, so a wide gap above trend is not part of the picture. Crowding evidence that can be observed is limited to the Q3 report about two weeks away, the overhang from the June offering, and inducement grants announced on 4 September 2026 and 2 October 2026. No SEC Form 4 insider sales or new offering documents have surfaced since the prior note.

Catalysts, next 30 days

• ~10 November 2026, est.: Q3 2026 results and corporate update. The date is estimated from the Q2 report on 11 August 2026 and prior-year timing, and Taysha has not confirmed it in anything reviewed. The report confirms or moves the Q4 2026 PPQ completion and the first-half 2027 pivotal interim and FDA feedback guidance.
• First half of 2027: pivotal six-month interim data and FDA feedback. Outside the 30-day window, but it is the event the case turns on.

What would change the view

The case breaks if the Q3 update moves PPQ completion past Q4 2026, delays the first-half 2027 pivotal interim, or discloses a treatment-related serious adverse event. It also breaks if the FDA signals that controlled data are required. On price, a daily close below $3.25 would extend the decline that began after the June offering and sit under the October low close of $3.73.

A clean Q3 report that reaffirms every timeline would leave the case intact but would not by itself change the evidence on FDA acceptance of a single-arm filing.

What it trades with

Taysha trades with small and mid-cap gene therapy and rare-disease developers, which react to rates, biotech funding conditions and FDA policy headlines. Its closest direct read-across is Neurogene, also developing a Rett syndrome gene therapy, whose Embolden topline is guided to the second half of 2027. Taysha has no product revenue, so its shares respond to clinical, regulatory and financing news rather than to earnings.